These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
295 related items for PubMed ID: 25241970
1. Improving clinical outcomes of chronic hepatitis B virus infection. Su TH, Kao JH. Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):141-54. PubMed ID: 25241970 [Abstract] [Full Text] [Related]
6. Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful? Buti M, Casillas R, Riveiro-Barciela M, Homs M, Tabernero D, Salcedo MT, Rodriguez-Frias F, Esteban R. J Clin Virol; 2015 Jul; 68():61-8. PubMed ID: 26071338 [Abstract] [Full Text] [Related]
7. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B]. Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J. Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911 [Abstract] [Full Text] [Related]
8. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study. Maklad S, Doss W, El Din SS, Hassan K, Zeid AA. Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505 [Abstract] [Full Text] [Related]
12. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F, Club Epatologi Ospedalieri (CLEO) Group. Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270 [Abstract] [Full Text] [Related]
17. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704 [Abstract] [Full Text] [Related]
18. Therapeutic strategies for chronic hepatitis B virus infection in 2008. Khokhar A, Afdhal NH. Am J Med; 2008 Dec; 121(12 Suppl):S33-44. PubMed ID: 19185073 [Abstract] [Full Text] [Related]
20. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. Boglione L, D'Avolio A, Cariti G, Gregori G, Burdino E, Baietto L, Cusato J, Ghisetti V, De Rosa FG, Di Perri G. Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449 [Abstract] [Full Text] [Related] Page: [Next] [New Search]